Tandem Diabetes Care (GB:0M0F)
UK Market

Tandem Diabetes Care Stock Analysis & Ratings

GB:0M0F Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.00 - $0.00
Previous Close$71.43
Average Volume (3M)746.00
Market Cap$4.57B
P/E RatioN/A
Next EarningsAug 04, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score4
EPS (TTM)0.00



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.



What was Tandem Diabetes Care’s price range in the past 12 months?
Tandem Diabetes Care lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is Tandem Diabetes Care’s market cap?
    Tandem Diabetes Care’s market cap is $4.57B.
      What is Tandem Diabetes Care’s price target?
      The average price target for Tandem Diabetes Care is $125.44. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $166.00 ,the lowest forecast is $100.00. The average price target represents 75.61% Increase from the current price of $71.43.
        What do analysts say about Tandem Diabetes Care?
        Tandem Diabetes Care’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.
          When is Tandem Diabetes Care’s upcoming earnings report date?
          Tandem Diabetes Care’s upcoming earnings report date is Aug 04, 2022 which is in 78 days.
            How were Tandem Diabetes Care’s earnings last quarter?
            Tandem Diabetes Care released its earnings results on May 04, 2022. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.07 by -$0.16.
              Is Tandem Diabetes Care overvalued?
              According to Wall Street analysts Tandem Diabetes Care’s price is currently Undervalued.
                Does Tandem Diabetes Care pay dividends?
                Tandem Diabetes Care does not currently pay dividends.
                What is Tandem Diabetes Care’s EPS estimate?
                Tandem Diabetes Care’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Tandem Diabetes Care have?
                Tandem Diabetes Care has 63,960,000 shares outstanding.
                  What happened to Tandem Diabetes Care’s price movement after its last earnings report?
                  Tandem Diabetes Care reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.07. Following the earnings report the stock price went down -14.997%.
                    Which hedge fund is a major shareholder of Tandem Diabetes Care?
                    Among the largest hedge funds holding Tandem Diabetes Care’s share is Consonance Capital. It holds Tandem Diabetes Care’s shares valued at 17M.


                      Tandem Diabetes Care Stock Analysis

                      The Tandem Diabetes Care stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Tandem Diabetes Care

                      Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

                      Similar Stocks
                      Price & Change
                      Johnson & Johnson

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis